The CSO Staying Ahead of the CDMO Curve

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Stefan Randl, Chief Scientific Officer at Siegfried.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Stefan, covering:   How his love of science, combined with a desire to get closer to the business, led him to leave Novartis His move from science into commercial roles, and how geographic relocations created a compound impact on his career The decision to leave a large pharma environment and join a smaller CDMO with both drug substance and drug product capabilities The importance of scientific innovation in creating competitive advantage in a busy and fragmented market Stefan’s role in shaping capability, R&D and technical investments, and why CDMOs must stay ahead of the curve by backing the areas they truly believe in How the need for accelerated speed to market is being driven by more assets, higher quality assets and increasingly complex products   Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!   Stefan Randl (1973) joined Siegfried in January 2025 as Chief Scientific Officer. Prior to joining Siegfried, he spent 16 years at Evonik, where he held various leadership positions in several regions, most recently as Vice President Innovation Management Health Care, based in Frankfurt, Germany, and as Vice President Drug Substance, based in Indiana, US. He also headed Sales & Services for Health Care in Asia, based in Tokyo.  He holds a PhD in Organic Chemistry from the Technische Universität Berlin and is a German citizen.   Connect with him on LinkedIn.